Alnylam to Webcast Presentation at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at the 39^th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 8:20 am ET, discussing unaudited fourth quarter and full year 2020 revenues. A Q&A breakout session will follow at 8:40 am ET. Investors can access a live audio webcast on the company's website, with a replay available within 48 hours. Alnylam is a leader in RNA interference therapeutics, working to develop innovative treatments for rare diseases.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 39^th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 8:20 am ET. This presentation will include an update on unaudited fourth quarter and full year 2020 global net product revenues. In addition, the Company will webcast the Q&A breakout session immediately following its presentation at 8:40 am ET.

A live audio webcast of both the presentation and breakout session will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), and OXLUMO™ (lumasiran). Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam has executed on and believes it has now exceeded its "Alnylam 2020" strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005774/en/

FAQ

What date is Alnylam presenting at the J.P. Morgan Healthcare Conference?

Alnylam Pharmaceuticals is presenting on January 11, 2021.

What time will Alnylam's presentation start?

The presentation will start at 8:20 am ET.

Where can I watch the Alnylam presentation live?

The live presentation can be accessed on Alnylam's website.

Will there be a Q&A session after Alnylam's presentation?

Yes, there will be a Q&A breakout session immediately following the presentation at 8:40 am ET.

How soon will a replay of Alnylam's presentation be available?

A replay will be available within 48 hours after the event.

What is Alnylam's focus in the biotechnology sector?

Alnylam focuses on RNA interference therapeutics for rare genetic and other diseases.